New Vaccination Guidelines, New Opportunity
Time to roll up the sleeves-again.
Last week the FDA, acting on the recommendation from the CDC’s Advisory Committee for Immunization Practices (ACIP), gave its approval to GSK to market Shingrix® to prevent shingles. The new guidance is based on a vaccine initially developed at the University of Colorado Health Sciences Center, now the University of Colorado Anschutz Medical Campus.
More than 99% of those older than 50 years are infected with Varicella Zoster Virus, and one in three Americans will develop shingles in their lifetime. The new recommendations apply to adults over the age of 50 including those previously received Zostavax®.
“The new recommendations mean up to 62 million more adults in the US should be immunized, approximately 42 million aged 50-59 years old and 20 million who have previously been vaccinated against shingles, which makes the vaccine critical,” GlaxoSmithKline said in a statement.
Shingrix® has demonstrated greater protection among older recipients, even though it requires two doses compared to one dose of Merck’s Zostavax®.
Zostavax® reduced the incidence of herpes zoster by 70% in 50–59-year-olds, by 64% in 60–69-year-olds and by 38% in people aged 70 and older in its pivotal trials. Shingrix® vaccine provided 97% protection against herpes zoster in patients aged 50 years and older, with a stable effect across all age groups (New Engl. J. Med. 28 Apr 2015).
The bottom line?
Claro™ Immunization Services is a truly integrated solution that streamlines the process for meeting unmet immunization needs and back-end reporting. With our solution, pharmacies can continue to build brand awareness while simultaneously encouraging existing patients to take advantage of new services.
Contact us to learn more about how your pharmacy can benefit from intelligent patient engagement and more from Claro™ Pharmacy Solutions.
Click here to learn more about our products:
Alphonse J. Sasso
VP of Business Development